Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bubs Australia Ltd. ( (AU:BUB) ) just unveiled an update.
Bubs Australia reported Q3 FY26 net revenue of $25.5 million, up 10% year on year, driven largely by the United States, where store distribution nearly doubled and revenue rose 43%, making the U.S. its largest market. The company is prioritising inventory build with a $25 million investment and is progressing through the final stages of U.S. FDA review, while maintaining total liquidity of $21.9 million despite negative operating cash flow.
Operational performance was tempered by geopolitical supply-chain disruptions, higher logistics and freight costs, and evolving global regulatory requirements that slowed border clearance and product release. Revenue declined in China, Australia and the rest of world due to out-of-stocks, competitive conditions and inventory allocation to higher-growth markets, with management emphasising disciplined execution, operational resilience and balance sheet flexibility amid the challenging environment.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
More about Bubs Australia Ltd.
Bubs Australia Ltd. is a Melbourne-based infant nutrition company focused on infant formula and toddler nutrition products. The company operates across key markets including the United States, China, Australia and selected rest-of-world regions, with a growing emphasis on U.S. retail distribution and strengthening its farm-to-formula supply chain capabilities.
Average Trading Volume: 1,147,337
Technical Sentiment Signal: Sell
Current Market Cap: A$98.35M
See more data about BUB stock on TipRanks’ Stock Analysis page.